Vaxart (VXRT) Competitors $0.34 -0.01 (-3.36%) As of 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. BNTC, CGC, CADL, RCKT, ALDX, LRMR, DRUG, ALT, DSGN, and OCGNShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Benitec Biopharma (BNTC), Canopy Growth (CGC), Candel Therapeutics (CADL), Rocket Pharmaceuticals (RCKT), Aldeyra Therapeutics (ALDX), Larimar Therapeutics (LRMR), Bright Minds Biosciences (DRUG), Altimmune (ALT), Design Therapeutics (DSGN), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Its Competitors Benitec Biopharma Canopy Growth Candel Therapeutics Rocket Pharmaceuticals Aldeyra Therapeutics Larimar Therapeutics Bright Minds Biosciences Altimmune Design Therapeutics Ocugen Benitec Biopharma (NASDAQ:BNTC) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation. Is BNTC or VXRT more profitable? Benitec Biopharma has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Benitec Biopharma's return on equity of -38.26% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Vaxart -122.63%-91.89%-38.40% Do analysts prefer BNTC or VXRT? Benitec Biopharma presently has a consensus target price of $26.00, indicating a potential upside of 99.65%. Vaxart has a consensus target price of $2.00, indicating a potential upside of 479.71%. Given Vaxart's higher probable upside, analysts plainly believe Vaxart is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in BNTC or VXRT? 52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 2.8% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, BNTC or VXRT? Benitec Biopharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Does the media favor BNTC or VXRT? In the previous week, Vaxart had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for Vaxart and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.64 beat Vaxart's score of 0.28 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxart 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, BNTC or VXRT? Benitec Biopharma has higher earnings, but lower revenue than Vaxart. Benitec Biopharma is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec BiopharmaN/AN/A-$21.75M-$1.51-8.62Vaxart$47.40M1.67-$66.95M-$0.25-1.38 SummaryBenitec Biopharma beats Vaxart on 9 of the 16 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.98M$2.81B$5.83B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-1.2822.6631.1625.99Price / Sales1.67760.87474.86122.97Price / CashN/A173.2237.1558.38Price / Book1.335.879.116.38Net Income-$66.95M$31.83M$3.26B$265.56M7 Day Performance-5.74%1.78%2.06%1.89%1 Month Performance-14.81%4.33%5.08%1.23%1 Year Performance-62.02%11.50%31.26%21.10% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart2.7376 of 5 stars$0.35-3.4%$2.00+479.7%-61.5%$78.98M$47.40M-1.28120News CoverageGap DownBNTCBenitec Biopharma1.4246 of 5 stars$12.71-2.3%$26.00+104.6%+41.7%$333.64M$80K-8.4220News CoverageCGCCanopy Growth0.7604 of 5 stars$1.37+5.4%N/A-80.6%$328.59M$225.65M-0.453,150Short Interest ↑High Trading VolumeCADLCandel Therapeutics2.6667 of 5 stars$5.96-2.1%$22.00+269.1%+10.1%$327.20M$120K-8.6460RCKTRocket Pharmaceuticals4.8827 of 5 stars$3.03-0.7%$16.33+439.1%-81.4%$326.94MN/A-1.21240Analyst ForecastAnalyst RevisionALDXAldeyra Therapeutics2.0997 of 5 stars$5.44+0.9%$9.50+74.6%+9.7%$325.83MN/A-6.4010LRMRLarimar Therapeutics2.2639 of 5 stars$3.90-2.7%$18.43+372.5%-54.7%$322.84MN/A-2.5030DRUGBright Minds Biosciences2.7539 of 5 stars$45.55+8.9%$83.25+82.8%+3,990.3%$320.67MN/A-48.98N/ATrending NewsAnalyst ForecastAnalyst RevisionALTAltimmune3.2732 of 5 stars$3.56-1.9%$17.40+388.8%-48.6%$314.21M$20K-3.0250Trending NewsDSGNDesign Therapeutics0.1681 of 5 stars$5.40+1.3%N/A-1.9%$307.53MN/A-4.8240OCGNOcugen1.2294 of 5 stars$1.04-1.0%$6.00+476.9%-21.7%$303.99M$4.05M-5.2080 Related Companies and Tools Related Companies Benitec Biopharma Competitors Canopy Growth Competitors Candel Therapeutics Competitors Rocket Pharmaceuticals Competitors Aldeyra Therapeutics Competitors Larimar Therapeutics Competitors Bright Minds Biosciences Competitors Altimmune Competitors Design Therapeutics Competitors Ocugen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access